Longeveron (LGVN) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Longeveron is the larger company by market cap ($5.6 million vs $5.4 million), about 1.0 times the size, while Universe Pharmaceuticals is growing revenue faster (-22.4% vs -49.9%). Universe Pharmaceuticals converts more of its revenue into profit, with a net margin of -20.6% versus -1893.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | UPC |
|---|---|---|
| Share price | $1.66 | $1.08 |
| Market cap | $5.60M | $5.43M |
| 1-day change | -8.79% | -20.59% |
| YTD return | — | -71.65% |
| 1-year return | — | -68.24% |
| 5-year return | — | -99.99% |
| EPS (TTM) | $-7.95 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.20M | $17.86B |
| Revenue growth (YoY) | -49.87% | -22.44% |
| Net income (latest FY) | $-22.70M | $-3.67B |
| Gross margin | 66.97% | 35.28% |
| Operating margin | -1942.20% | -16.33% |
| Net margin | -1893.58% | -20.56% |
| 52-week high | $12.30 | $17.96 |
| 52-week low | $1.31 | $1.05 |
| Distance from 52-week high | -86.50% | -93.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +3589.76% | — |
| Average volume | 115.35K | 176.76K |
| Shares outstanding | 3.23M | 5.01M |
| Employees | 38 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Universe Pharmaceuticals is more profitable, keeping -20.6 cents of every revenue dollar as net income versus -1893.6 cents for Longeveron.
- Universe Pharmaceuticals grew revenue faster in its latest fiscal year (-22.44% vs -49.87%).
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
LGVN vs UPC FAQ
Which is bigger, Longeveron or Universe Pharmaceuticals?
Longeveron (LGVN) is larger, with a market capitalization of $5.60M compared with $5.43M for Universe Pharmaceuticals (UPC).
Are Longeveron and Universe Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.